Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653833 · ClinicalTrials.gov registry record · Early Phase 1
The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy
A Early Phase 1 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT02653833 is a Early Phase 1 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT02653833, a Early Phase 1 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot study tests the hypothesis that the medication nitric oxide extract from beetroot juice improves blood flow to the skeletal muscle during exercise. The investigators will use cutting edge technology with contrast enhanced ultrasound to visualize the microvascular blood supply to the forearm. Animal studies have shown reversal of muscle damage with improved delivery of blood to the exercising muscle. This research aims to understand the mechanism of action of this medication in a way it has never been studied before. The results may help benefit individuals with muscular Dystrophy in the future.
Interventions
- DRUG Tadalafil 20 MG
- OTHER beetroot juice extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653833
The ClinicalTrials.gov registry entry for NCT02653833 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tadalafil 20 MG is the first listed.
NCT02653833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653833 about?
NCT02653833 is a clinical study titled "The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy". This pilot study tests the hypothesis that the medication nitric oxide extract from beetroot juice improves blood flow to the skeletal muscle during exercise. The investigators will use cutting edge technology with contrast enhanced ultrasound to visualize the microvascular blood supply to the forea...
What is the current status of trial NCT02653833?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2017-11-01. Estimated completion is 2018-09-01.
What interventions are being tested in trial NCT02653833?
The interventions under investigation include: Tadalafil 20 MG (DRUG), beetroot juice extract (OTHER).
Who is sponsoring clinical trial NCT02653833?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.